Envision Healthcare - Ein Medizindienstleister
Seite 5 von 6 Neuester Beitrag: 27.02.18 22:47 | ||||
Eröffnet am: | 27.12.13 13:15 | von: Spaetschicht | Anzahl Beiträge: | 131 |
Neuester Beitrag: | 27.02.18 22:47 | von: Spaetschicht | Leser gesamt: | 38.341 |
Forum: | Börse | Leser heute: | 2 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 | 4 | | 6 > |
Greenwood Village, Colorado & NASHVILLE, Tenn .-- (. BUSINESS WIRE ) - Envision Healthcare Holdings, Inc. (Envision) (NYSE: EVHC) und AMSURG Corp. (AMSURG) (NASDAQ: AMSG) gab heute bekannt , dass sie erhalten haben , feststellen, dass die Kartellbehörde des Staates Florida Generalstaatsanwaltschaft seine Untersuchung über die geplante Fusion von Envision und AMSURG und keine Maßnahmen ergreift, geschlossen hat.
Die Wartezeit nach dem Hart-Scott-Rodino Antitrust Improvements Act von 1976 in Bezug auf die US Federal Trade Commission Überprüfung der bevorstehenden Fusion abgelaufen letzte Woche, erfüllt eine der Bedingungen für den Abschluss der Fusion. Die Transaktion steht unter dem Vorbehalt der üblichen Abschlussbedingungen, einschließlich der Genehmigung durch die Aktionäre beider Envision und AMSURG.
Auch Amsurg (Merger) kauft fleißig dazu. Leider funktionieren die Links von Streetinsider bei Ariva nicht richtig...
http://www.google.com/...=NASDAQ%3AAMSG&ei=29HRV9mbCYigsgH10IWICQ
Sheridan, the Physician Services division of AMSURG Corp. (Nasdaq: AMSG), has further expanded its anesthesiology services business and entered the Southern California market with its acquisition of Ambulatory Anesthesia Associates, Inc. (AAA) and Genesis Anesthesia Services, Inc. (Genesis). The combined group employs 27 physicians covering six independent facilities, with Marina Del Rey Hospital representing its largest relationship.
Robert J. Coward, President of Physician Services, noted, “Sheridan’s acquisition of AAA and Genesis represents an important expansion of our ambulatory anesthesia business, provides initial entry into the Southern California market and further strengthens our presence in California as a whole. We are proud this outstanding group of clinicians has chosen Sheridan as its partner in delivering excellent patient care and outstanding service to client surgical facilities.”
Robert J. Coward, Präsident der Dienste für Ärzte, stellte fest: "Sheridans Erwerb von AAA und Genesis stellt eine wichtige Erweiterung unseres ambulanten Anästhesie Geschäft, liefert erste Einstieg in den Southern California Markt und stärkt unsere Präsenz in Kalifornien als Ganzes. Wir sind stolz, diese herausragende Gruppe von Klinikern Sheridan als Partner bei der Bereitstellung von ausgezeichneten Patientenversorgung und herausragenden Service für Client-chirurgische Einrichtungen ausgewählt hat. "
Gainey McKenna & Egleston kündigt eine Strafanzeige Class Action hat sich gegen Envision Healthcare Holdings, Inc. (EVHC) eingereicht
https://translate.google.de/...c-EVHC.html&edit-text=&act=url
Highlights:
Net revenue of $1.64 billion, an increase of 19.8%;
Net income of $25.9 million, an increase of 50.2%;
Adjusted EBITDA of $180.7 million, an increase of 26.8%;
GAAP diluted earnings per share (EPS) was $0.13, an increase of 44.4%; and
Adjusted diluted EPS was $0.36, an increase of 20.0%.
“In spite of lower sector volume growth in the period, our third quarter reflects strong operating results at EmCare, including encouraging progress at Evolution Health, and performance improvement at AMR’s Rural Metro operations,” said William A. Sanger, chairman, president and chief executive officer of Envision. “Rural Metro’s margins improved, driven by continued integration into AMR’s operations and technology platforms. Our results at Evolution Health improved as we realized benefits from our participation in bundled payment models and medical cost savings from our contract with a Florida health plan.
“The strategic investments we have made at Envision to expand our scale and scope continue to provide unique opportunities for the company and our stakeholders. We believe these investments will be further enhanced by the merger between Envision and AMSURG Corp., which is expected to be completed this year.”
Amsurg und Envision fusioneren Ende des Jahres. Wenn die Präsidentschaftskandidaten nicht zu sehr am Kurs rütteln sollte es eigentlich wieder Bergauf gehen. Zumal auch Wells Fargo die Daumen hebt. Leider nur in Echtzeit bei Guidants
Wells Fargo stuft Envision Healthcare Holdings von Marketperform auf Outperform hoch / Quelle: Guidants News http://news.guidants.com
Wells Fargo stuft AmSurg von Marketperform auf Outperform hoch / Quelle: Guidants News http://news.guidants.com
AmSurg Corp. earnings at a glance:
-Earnings (Q3): $64.94 Mln. vs. $53.05 Mln. last year.
-Earnings Growth (Y-o-Y): 22.4%
-EPS (Q3): $1.13 vs. $1.03 last year.
-EPS Growth (Y-o-Y): 9.7%
-Analysts Estimate: $1.13
-Revenue (Q3): $968.82 Mln vs. $712.72 Mln last year.
-Revenue Change (Y-o-Y): 35.9%
Envision Healthcare and AMSURG Shareholders Approve Merger
Holders of over 82 percent of shares of Envision’s common stock outstanding and entitled to vote, or over 96 percent of votes cast, voted to approve the merger. Holders of 88 percent of shares of AMSURG’s common stock outstanding and entitled to vote, or over 99 percent of votes cast, voted to approve the merger. Envision and AMSURG will each file a Form 8-K later today disclosing the full voting results
8K
http://api40.10kwizard.com/cgi/convert/pdf/...e=-1&pdf=1&dn=1
The companies expect to complete the merger on Dec 1, 2016. Notably, the merger has been sealed at a fixed exchange ratio of 0.334 AmSurg shares for each Envision share.
Mittelfristig sollte der neue US-Präsident Donald Trump nach Meinung von Ingo Grabowsky, Vertriebsdirektor der Lacuna AG, sogar vorteilhaft für den Gesundheitsbereich sein.
Regensburg (GodmodeTrader.de) - Donald Trump hat überraschend die US-Wahl gewonnen. Eines seiner zentralen Wahlversprechen war es, die umstrittene Gesundheitsreform seines Vorgängers, Obamacare, umgehend wieder rückgängig zu machen. Damit könnten dem Gesundheitssektor sichere Einnahmen wegbrechen. Mittelfristig sollte Präsident Trump sogar vorteilhaft für den Gesundheitsbereich sein. Zumal die Bewertungen nach leichten Verlusten im Wahlkampfgetöse derzeit günstig sind und Trump bereits seine radikalsten Aussagen aus dem Wahlkampf relativiert hat, wie Ingo Grabowsky, Vertriebsdirektor der Lacuna AG, in einem aktuellen Marktkommentar schreibt. / Quelle: Guidants News http://news.guidants.com
69.91 +47.33 (209.61%)
After Hours: 69.91 0.00 (0.00%)
http://www.consumereagle.com/...lthcare-holdings-inc-nyseevhc/267639/
Shares of Envision Healthcare Holdings, Inc. (NYSE:EVHC) are climbing higher mid-day as the stock reaches today’s top winners list. At the time of writing, the stock had reached $70.00. This represents a change from the opening price of 5.66%. The year-to-date performance of the stock is -13.05%. The monthly stock performance comes in at 13.30%. For the quarter, shares are performing at 5.27%. Weekly performance analysis shows the equity at 3.01%.
Envision Healthcare Corp will be co-headquartered in Greenwood Village and Nashville, the companies said. It will trade on the New York Stock Exchange under Envision’s ticket symbol, EVHC, starting Friday.
The merger leaves Envision shareholders owning 53 percent of the combined company and AmSurg investors with 47 percent.
Both companies provide physician services, and Envision is a major ambulance and medical-transportation operator through its American Medical Response division.
Envision posted 2015 revenue of $5.4 billion and profit of $140 million. Its main divisions, in addition to AMR, are EmCare and Evolution Health.
http://www.bizjournals.com/denver/news/2016/12/01/...with-amsurg.html
Etwas wird noch passieren entweder wird die Aktienanzahl oder der Wert durch 3 geteilt . Auf jeden Fall ist Envision bald im S&P 500 gelistet (#116)
FOLGENDE WERTPAPIERE WERDEN AM 05.12.2016 EX KAPITALMASSNAHME GEHANDELT.
THE FOLLOWING SHARES ARE TRADED EX CAPITAL ADJUSTMENT ON 05.12.2016.
INSTR EXCH ISIN INSTRUMENT NAME
IDX XFRA US45841V1098 INTERACTIVE INT.GR.DL-,01
XFRA US00504W3088 ACTIVE POWER INC. DL-,001
TEB XFRA US88164L1008 TESSERA TECH.INC. DL-,001
DTS XFRA US23335C1018 DTS INC. DL-,0,0001
XFRA KYG8169R1039 SINO RESOURCES GRP HD-,01
2PR1 XFRA TH0878010R17 PRUKSA REAL EST.-NVDR-BA1
KYW XFRA BMG8181C1001 SKYWORTH DIGI.HLDGS HD-10
E4V XFRA US29413U1034 ENVISION HEALTH.HD.DL-,01
CGI XFRA US2236221014 COWEN GROUP CL.A DL -,01
AJH XFRA US03232P4054 AMSURG CORP. DL-,01
WKN: A2DHL5
ISIN: US29414D1000
kleiner Blick auf den S&P
http://cincysportszone.com/...healthcare-corporation-nyseevhc/126661/
Long-term growth (LTG) is an investing strategy where a stock will (hopefully) grow in value for a relatively long period of time. Long-term growth should be considered to be a relative term, due to different styles and goals of investors, but the endgame is the same.
A “buy-and-hold” investor will consider long-term growth as a longer time period then a day trader will. The buy-and-hold strategy looks ahead farther into the future, giving short-term price swings less consideration as long as the fundamentals stay the same. A trader is looking more closely at a weekly, or shorter, time frame and is more interested in immediate price fluctuations.
NASHVILLE, Tenn. & GREENWOOD VILLAGE, Colo., Feb 28, 2017 (BUSINESS WIRE) -- Envision Healthcare Corporation (“Envision”) EVHC, -5.33% today reported financial results for the three months and 12 months ended December 31, 2016. Envision was formed December 1, 2016, with the merger (“the Merger”) of AMSURG Corp. (“AMSURG”) and Envision Healthcare Holdings, Inc. (“EHH”). As a result of the Merger, the Company’s financial results included in today’s press release reflect AMSURG’s results for the 12 months ended December 31, 2016, and EHH’s results for December 1 through December 31, 2016.
Highlights for the Fourth Quarter of 2016:
Net revenues of $1.39 billion;
A net loss attributable to Envision common stockholders of $137.8 million, or $1.84 per share, as a result of merger-related costs, including an impairment charge of $221 million primarily related to the planned phase-out of the Sheridan trade name, transaction and integration costs and debt extinguishment costs;
Adjusted net earnings of $92.0 million;
Adjusted net earnings per diluted share of $1.15; and
Adjusted EBITDA of $208.7 million.
Highlights for 2016:
Net revenues of $3.70 billion, which consists of $3.15 billion related to AMSURG for 2016 and $546.0 million from EHH for the month of December;
Net loss attributable to common stockholders of $27.7 million, or $0.47 per share;
Adjusted net earnings of $266.7 million;
Adjusted net earnings per diluted share of $4.23;
Adjusted EBITDA of $631.0 million; and
A reconciliation of all historical GAAP and non-GAAP financial results is included on page 6 of this press release. Envision is also including certain supplemental projected adjusted EBITDA and same-contract performance of its results for the full year of 2016. The supplemental projected information, which includes the results of EHH for the 12 months ended December 31, 2016, and is included on page 9 of this press release, is a non-GAAP measure being provided for informational purposes only.
“We are making great strides in integrating the operations of AMSURG and Envision following our transformative merger of equals, and we are on track to achieve our target cost synergies,” said Christopher A. Holden, President and Chief Executive Officer of Envision. “Since completing the merger, we are executing on an ambitious plan that includes a strategic review of our core strengths, and we will explore strategic options that may lead to a redeployment of our resources in order to increase stockholder value.
“Our results for the 2016 fourth quarter were impacted by lower-than-anticipated volume growth in both our physician services and medical transportation segments, which we have taken into account when developing our outlook for 2017. We remain committed to achieving operational excellence at Envision, and we are excited about the opportunities to grow this organization. During the fourth quarter of 2016, we completed three Physician Services acquisitions in anesthesia and neonatology. During the first quarter of 2017, we have completed four acquisitions in anesthesia, emergency medicine, radiology and ambulatory services. These transactions, as well as our ongoing discussions with healthcare providers and health systems, validate the strong market positioning and potential Envision has as an integrated and scaled national provider across a broad continuum of clinical network solutions.”
Following completion of the Merger, Envision is reporting its results for three segments: Physician Services, which includes AMSURG’s legacy Sheridan Healthcare and EHH’s legacy EmCare and Evolution Health, Medical Transportation and Ambulatory Services.
70.00 -2.41 (-3.33%)
After Hours: 62.00 -8.00 (-11.43%)
Feb 28, 4:43PM EST